Characterising the shared genetic determinants of bipolar disorder, schizophrenia and risk-taking.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
08 09 2021
Historique:
received: 19 02 2021
accepted: 18 08 2021
revised: 19 07 2021
entrez: 9 9 2021
pubmed: 10 9 2021
medline: 12 10 2021
Statut: epublish

Résumé

Increased risk-taking is a central component of bipolar disorder (BIP) and is implicated in schizophrenia (SCZ). Risky behaviours, including smoking and alcohol use, are overrepresented in both disorders and associated with poor health outcomes. Positive genetic correlations are reported but an improved understanding of the shared genetic architecture between risk phenotypes and psychiatric disorders may provide insights into underlying neurobiological mechanisms. We aimed to characterise the genetic overlap between risk phenotypes and SCZ, and BIP by estimating the total number of shared variants using the bivariate causal mixture model and identifying shared genomic loci using the conjunctional false discovery rate method. Summary statistics from genome wide association studies of SCZ, BIP, risk-taking and risky behaviours were acquired (n = 82,315-466,751). Genomic loci were functionally annotated using FUMA. Of 8.6-8.7 K variants predicted to influence BIP, 6.6 K and 7.4 K were predicted to influence risk-taking and risky behaviours, respectively. Similarly, of 10.2-10.3 K variants influencing SCZ, 9.6 and 8.8 K were predicted to influence risk-taking and risky behaviours, respectively. We identified 192 loci jointly associated with SCZ and risk phenotypes and 206 associated with BIP and risk phenotypes, of which 68 were common to both risk-taking and risky behaviours and 124 were novel to SCZ or BIP. Functional annotation implicated differential expression in multiple cortical and sub-cortical regions. In conclusion, we report extensive polygenic overlap between risk phenotypes and BIP and SCZ, identify specific loci contributing to this shared risk and highlight biologically plausible mechanisms that may underlie risk-taking in severe psychiatric disorders.

Identifiants

pubmed: 34497263
doi: 10.1038/s41398-021-01576-4
pii: 10.1038/s41398-021-01576-4
pmc: PMC8426401
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

466

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH109897
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH075916
Pays : United States
Organisme : NIMH NIH HHS
ID : U01 MH103392
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH109677
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH084053
Pays : United States
Organisme : NIDA NIH HHS
ID : HHSN271201300031C
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH110921
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH066392
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH080405
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH085542
Pays : United States
Organisme : NIMH NIH HHS
ID : R37 MH057881
Pays : United States
Organisme : NIBIB NIH HHS
ID : R01 EB000790
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS057198
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH097276
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG002219
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH093725
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005138
Pays : United States
Organisme : NIMH NIH HHS
ID : P50 MH096891
Pays : United States

Informations de copyright

© 2021. The Author(s).

Références

Ferrari AJ, Stockings E, Khoo JP, Erskine HE, Degenhardt L, Vos T, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016. https://doi.org/10.1111/bdi.12423 .
Pompili M, Gonda X, Serafini G, Innamorati M, Sher L, Amore M. et al. Epidemiology of suicide in bipolar disorders: a systematic review of the literature. Bipolar Disord. 2013;15:457–90.
pubmed: 23755739 doi: 10.1111/bdi.12087
Brugnoli R, Novick D, Haro JM, Rossi A, Bortolomasi M, Frediani S, et al. Risk factors for suicide behaviors in the observational schizophrenia outpatient health outcomes (SOHO) study. BMC Psychiatry. 2012;12:1.
doi: 10.1186/1471-244X-12-83
DE Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10:52–77.
doi: 10.1002/j.2051-5545.2011.tb00014.x
Brailovskaia J, Schillack H, Assion HJ, Horn H, Margraf J. Risk-taking propensity and (un)healthy behavior in Germany. Drug Alcohol Depend. 2018;192:324–8.
pubmed: 30316034 doi: 10.1016/j.drugalcdep.2018.08.027
Rieser NM, Shaul L, Blankers M, Koeter M, Schippers GM, Goudriaan AE. The predictive value of impulsivity and risk-taking measures for substance use in substance dependent offenders. Front Behav Neurosci. 2019;13:192
pubmed: 31680889 pmcid: 6798264 doi: 10.3389/fnbeh.2019.00192
Müller A, Claes L, Smits D, Brähler E, De Zwaan M. Prevalence and correlates of self-harm in the German general population. PLoS One. 2016;11:e0157928.
pubmed: 27362348 pmcid: 4928828 doi: 10.1371/journal.pone.0157928
Strawbridge RJ, Ward J, Cullen B, Tunbridge EM, Hartz S, Bierut L, et al. Genome-wide analysis of self-reported risk-taking behaviour and cross-disorder genetic correlations in the UK Biobank cohort. Transl Psychiatry. 2018;8:1–11.
doi: 10.1038/s41398-017-0079-1
Leigh BC. Peril, chance, adventure: Concepts of risk, alcohol use and risky behavior in young adults. Addiction. 1999. https://doi.org/10.1046/j.1360-0443.1999.9433717.x .
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Washington: American Psychiatric Publishing; 2013.
World Health Organization. The ICD-10 classification of mental and behavioural disorders: diagnostic criteria for research. Geneva: WHO; 1993.
Meade CS, Fitzmaurice GM, Sanchez AK, Griffin ML, McDonald LJ, Weiss RD. The relationship of manic episodes and drug abuse to sexual risk behavior in patients with co-occurring bipolar and substance use disorders: a 15-month prospective analysis. AIDS Behav. 2011;15:1829–33.
pubmed: 20859672 pmcid: 3191230 doi: 10.1007/s10461-010-9814-9
Najt P, Perez J, Sanches M, Peluso MA, Glahn D, Soares JC. Impulsivity and bipolar disorder. Eur Neuropsychopharmacol. 2007;17:313–20.
pubmed: 17140772 doi: 10.1016/j.euroneuro.2006.10.002
Chandler RA, Wakeley J, Goodwin GM, Rogers RD. Altered risk-aversion and risk-seeking behavior in bipolar disorder. Biol Psychiatry. 2009;66:840–6.
pubmed: 19615669 doi: 10.1016/j.biopsych.2009.05.011
Hıdıroğlu C, Demirci Esen Ö, Tunca Z, Neslihan Gűrz Yalçìn S, Lombardo L, Glahn DC, et al. Can risk-taking be an endophenotype for bipolar disorder? A study on patients with bipolar disorder type I and their first-degree relatives. J Int Neuropsychol Soc. 2013;19:474–82.
pubmed: 23410848 pmcid: 4180758 doi: 10.1017/S1355617713000015
Jones RM, Arlidge J, Gillham R, Reagu S, van den Bree M, Taylor PJ. Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: Systematic review and meta-analysis. Br J Psychiatry. 2011;198:93–8.
pubmed: 21282779 doi: 10.1192/bjp.bp.110.083030
van Schalkwyk GI, Beyer C, Johnson J, Deal M, Bloch MH. Antipsychotics for aggression in adults: a meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2018;81:452–8.
pubmed: 28754408 doi: 10.1016/j.pnpbp.2017.07.019
Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, et al. Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. J Nerv Ment Dis. 2006;194:164–72.
pubmed: 16534433 doi: 10.1097/01.nmd.0000202575.79453.6e
de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–57.
pubmed: 15949648 doi: 10.1016/j.schres.2005.02.010
Rund BR. A review of factors associated with severe violence in schizophrenia. Nord J Psychiatry. 2018;72:561–71.
pubmed: 30099913 doi: 10.1080/08039488.2018.1497199
Fischer BA, McMahon RP, Kelly DL, Wehring HJ, Meyer WA, Feldman S, et al. Risk-taking in schizophrenia and controls with and without cannabis dependence. Schizophr Res. 2015;161:471–7.
pubmed: 25467541 doi: 10.1016/j.schres.2014.11.009
Reddy LF, Lee J, Davis MC, Altshuler L, Glahn DC, Miklowitz DJ, et al. Impulsivity and risk taking in bipolar disorder and schizophrenia. Neuropsychopharmacology 2014;39:456–63.
pubmed: 23963117 doi: 10.1038/npp.2013.218
Kaladjian A, Jeanningros R, Azorin J-M, Anton J-L, Mazzola-Pomietto P. Impulsivity and neural correlates of response inhibition in schizophrenia. Psychol Med. 2011;41:291–9.
pubmed: 20406530 doi: 10.1017/S0033291710000796
Mason L, O’sullivan N, Montaldi D, Bentall RP, El-Deredy W. Decision-making and trait impulsivity in bipolar disorder are associated with reduced prefrontal regulation of striatal reward valuation. Brain 2014;137:2346–55.
pubmed: 25009169 pmcid: 4107743 doi: 10.1093/brain/awu152
Lee J, Choi S, Kang J, Won E, Tae WS, Lee MS, et al. Structural characteristics of the brain reward circuit regions in patients with bipolar I disorder: a voxel-based morphometric study. Psychiatry Res Neuroimaging. 2017;269:82–9.
pubmed: 28963911 doi: 10.1016/j.pscychresns.2017.09.013
Avsar KB, Weller RE, Cox JE, Reid MA, White DM, Lahti AC. An fMRI investigation of delay discounting in patients with schizophrenia. Brain Behav. 2013;3:384–401.
pubmed: 24381810 pmcid: 3869680 doi: 10.1002/brb3.135
Schiffer B, Müller BW, Scherbaum N, Forsting M, Wiltfang J, Leygraf N, et al. Impulsivity-related brain volume deficits in schizophrenia-addiction comorbidity. Brain 2010;133:3093–103.
pubmed: 20647266 doi: 10.1093/brain/awq153
Tu PC, Kuan YH, Li CT, Su TP. Structural correlates of trait impulsivity in patients with bipolar disorder and healthy controls: a surface-based morphometry study. Psychol Med. 2017;47:1292–9.
pubmed: 28077175 doi: 10.1017/S0033291716003299
Hoptman MJ, Ardekani BA, Butler PD, Nierenberg J, Javitt DC, Lim KO. DTI and impulsivity in schizophrenia: a first voxelwise correlational analysis. Neuroreport 2004;15:2467–70.
pubmed: 15538176 pmcid: 1550497 doi: 10.1097/00001756-200411150-00007
Scholz V, Houenou J, Kollmann B, Duclap D, Poupon C, Wessa M. Dysfunctional decision-making related to white matter alterations in bipolar i disorder. J Affect Disord. 2016;194:72–9.
pubmed: 26803778 doi: 10.1016/j.jad.2015.12.019
Sugam JA, Carelli RM. Rolling the dice: the importance of mesolimbic dopamine signaling in risky decision making. Neuropsychopharmacology 2013;38:248.
pubmed: 23147490 doi: 10.1038/npp.2012.173
Voon V, Gao J, Brezing C, Symmonds M, Ekanayake V, Fernandez H, et al. Dopamine agonists and risk: impulse control disorders in Parkinson’s disease. Brain 2011;134:1438–46.
pubmed: 21596771 pmcid: 3097893 doi: 10.1093/brain/awr080
Karlsson Linnér R, Biroli P, Kong E, Meddens S, Wedow R, Fontana MA, et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nat Genet. 2019;51:245–57.
pubmed: 30643258 doi: 10.1038/s41588-018-0309-3
Strawbridge RJ, Ward J, Lyall LM, Tunbridge EM, Cullen B, Graham N, et al. Genetics of self-reported risk-taking behaviour, trans-ethnic consistency and relevance to brain gene expression. Transl Psychiatry. 2018;8:1–11.
doi: 10.1038/s41398-018-0236-1
Smeland OB, Frei O, Dale AM, Andreassen OA. The polygenic architecture of schizophrenia-rethinking pathogenesis and nosology. Nat Res. 2020;16:366–79.
Smeland OB, Frei O, Shadrin A, O'Connell K, Fan CC, Bahrami S. et al. Discovery of shared genomic loci using the conditional false discovery rate approach. Hum Genet. 2019;139:1–10.
Smeland OB, Bahrami S, Frei O, Shadrin A, O'Connell K, Savage J, et al. Genome-wide analysis reveals extensive genetic overlap between schizophrenia, bipolar disorder, and intelligence. Mol Psychiatry. 2019;25:844–53.
pubmed: 30610197 doi: 10.1038/s41380-018-0332-x
Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51:793–803.
pubmed: 31043756 pmcid: 6956732 doi: 10.1038/s41588-019-0397-8
Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50:381–9.
pubmed: 29483656 pmcid: 5918692 doi: 10.1038/s41588-018-0059-2
Psychiatric SWG of the et al. Bakphrenia-associated genetic loci. Nature. 2014;511:421–7.
Lee SH, DeCandia TR, Ripke S, Yang J, et al. Estimating the proportion of variation in susceptibility to schizophrenia captured by common SNPs. Nat Genet. 2012;44:247–50.
pubmed: 22344220 pmcid: 3327879 doi: 10.1038/ng.1108
Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, et al. LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat Genet. 2015;47:291–5.
pubmed: 25642630 pmcid: 4495769 doi: 10.1038/ng.3211
Frei O, Holland D, Smeland OB, Shadrin AA, Fan CC, Maeland S, et al. Bivariate causal mixture model quantifies polygenic overlap between complex traits beyond genetic correlation. Nat Commun. 2019;10:1–11.
doi: 10.1038/s41467-019-10310-0
Cross-Disorder Group of the Psychiatric Genomics C, Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45:984–94.
doi: 10.1038/ng.2711
Girard SL, Xiong L, Dion PA, Rouleau GA. Where are the missing pieces of the schizophrenia genetics puzzle? Curr Opin Genet Dev. 2011;21:310–6.
pubmed: 21277191 doi: 10.1016/j.gde.2011.01.001
Gershon ES, Alliey-Rodriguez N, Liu C. After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. Am J Psychiatry. 2011;168:253–6.
pubmed: 21285144 pmcid: 6760656 doi: 10.1176/appi.ajp.2010.10091340
Visscher PM, Wray NR, Zhang Q, Sklar P, McCarthy MI, Brown MA, et al. 10 Years of GWAS discovery: biology, function, and translation. Am J Hum Genet. 2017;101:5–22.
pubmed: 28686856 pmcid: 5501872 doi: 10.1016/j.ajhg.2017.06.005
Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, et al. Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Hum Genet. 2013;92:197–209.
pubmed: 23375658 pmcid: 3567279 doi: 10.1016/j.ajhg.2013.01.001
Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman J, Qiao Z, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet. 2021. https://doi.org/10.1038/s41588-021-00857-4 .
Becker A, Deckers T, Dohmen T, Falk A, Kosse F. The relationship between economic preferences and psychological personality measures. Annu Rev Econ. 2012;4:453–78.
doi: 10.1146/annurev-economics-080511-110922
Falk A, Becker A, Dohmen TJ, Enke B, Huffman D, Sunde U. The nature and predictive power of preferences: global evidence. SSRN Electronic Journal. 2015. https://doi.org/10.2139/ssrn.2691910 .
Dohmen T, Falk A, Huffman D, Sunde U, Schupp J, Wagner GG. Individual risk attitudes: measurement, determinants, and behavioral consequences. J Eur Econ Assoc. 2011;9:522–50.
doi: 10.1111/j.1542-4774.2011.01015.x
Beauchamp JP, Cesarini D, Johannesson M. The psychometric and empirical properties of measures of risk preferences. J Risk Uncertain. 2017;54:203–37.
doi: 10.1007/s11166-017-9261-3
Barsky RB, Juster FT, Kimball MS, Shapiro MD. Preference parameters and behavioral heterogeneity: an experimental approach in the health and retirement study. Q J Econ. 1997;112:537–79.
doi: 10.1162/003355397555280
Andreassen OA, Thompson WK, Schork AJ, Ripke S, Mattingsdal M, Kelsoe JR, et al. Improved detection of common variants associated with schizophrenia and bipolar disorder using pleiotropy-informed conditional false discovery rate. PLoS Genet. 2013;9:e1003455.
pubmed: 23637625 pmcid: 3636100 doi: 10.1371/journal.pgen.1003455
Smeland OB, Wang Y, Frei O, Li W, Hibar DP, Franke B, et al. Genetic overlap between schizophrenia and volumes of hippocampus, putamen, and intracranial volume indicates shared molecular genetic mechanisms. Schizophr Bull. 2018;44:854–64.
pubmed: 29136250 doi: 10.1093/schbul/sbx148
Smeland OB, Shadrin A, Bahrami S, Broce I, Tesli M, Frei O. et al. Genome-wide association analysis of Parkinsonas disease and schizophrenia reveals shared genetic architecture and identifies novel risk loci. Biol Psychiatry. 2020;89:227–35.
pubmed: 32201043 doi: 10.1016/j.biopsych.2020.01.026 pmcid: 7416467
Bahrami S, Steen NE, Shadrin A, O'Connell K, Frei O, Bettella F. et al. Shared genetic loci between body mass index and major psychiatric disorders: a genome-wide association study. JAMA Psychiatry. 2020;77:503–12.
pubmed: 31913414 doi: 10.1001/jamapsychiatry.2019.4188
Lam M, Chen CY, Li Z, Martin AR, Bryois J, Ma X, et al. Comparative genetic architectures of schizophrenia in East Asian and European populations. Nat Genet. 2019;51:1670–8.
pubmed: 31740837 pmcid: 6885121 doi: 10.1038/s41588-019-0512-x
Le Hellard S, Wang Y, Witoelar A, Zuber V, Bettella F, Hugdahl K, et al. Identification of gene loci that overlap between schizophrenia and educational attainment. Schizophr Bull. 2017;43:654–64.
pubmed: 27338279
O'connell KS, Shadrin A, Bahrami S, Smeland OB, Bettella F, Frei O, et al. Identification of genetic overlap and novel risk loci for attention-deficit/hyperactivity disorder and bipolar disorder. Mol Psychiatry. 2019. https://doi.org/10.1038/s41380-019-0613-z .
Lee PH, et al. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell 2019;179:1469–82.
doi: 10.1016/j.cell.2019.11.020
Mullins N et al. Genome-wide association study of over 40,000 bipolar disorder cases provides novel biological insights. MedRxiv. 2020. https://doi.org/10.1101/2020.09.17.2018705 .
Drange OK, Smeland OB, Shadrin AA, Finseth PI, Witoelar A, Frei O, et al. Genetic overlap between Alzheimer’s disease and bipolar disorder implicates the MARK2 and VAC14 genes. Front Neurosci. 2019;13:220.
pubmed: 30930738 pmcid: 6425305 doi: 10.3389/fnins.2019.00220
Andreassen OA, Thompson WK, Dale AM. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. Mol Psychiatry. 2015;20:207–14.
pubmed: 24468824 doi: 10.1038/mp.2013.195
van der Meer D, Rokicki J, Kaufmann T, Córdova-Palomera A, Moberget T, Alnæs D, et al. Brain scans from 21,297 individuals reveal the genetic architecture of hippocampal subfield volumes. Mol Psychiatry. 2020;25:3053–65.
pubmed: 30279459 doi: 10.1038/s41380-018-0262-7
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498–504.
pubmed: 14597658 pmcid: 403769 doi: 10.1101/gr.1239303
Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8:1826.
pubmed: 29184056 pmcid: 5705698 doi: 10.1038/s41467-017-01261-5
Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, Kasowski M, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22:1790–7.
pubmed: 22955989 pmcid: 3431494 doi: 10.1101/gr.137323.112
Herwig R, Hardt C, Lienhard M, Kamburov A. Analyzing and interpreting genome data at the network level with ConsensusPathDB. Nat Protoc. 2016;11:1889–907.
pubmed: 27606777 doi: 10.1038/nprot.2016.117
Miller JA, Ding SL, Sunkin SM, Smith KA, Ng L, Szafer A, et al. Transcriptional landscape of the prenatal human brain. Nature 2014;508:199–206.
pubmed: 24695229 pmcid: 4105188 doi: 10.1038/nature13185
BrainSpan. BrainSpan Atlas of the Developing Human Brain. 2010. http://www.brainspan.org/ . Accessed 16 October 2020.
Bahl E, Koomar T, Michaelson JJ. cerebroViz: an R package for anatomical visualization of spatiotemporal brain data. Bioinformatics 2017;33:762–3.
pubmed: 28011779 doi: 10.1093/bioinformatics/btw726
Sanchez-Roige S, Fontanillas P, Elson SL, Gray JC, de Wit H, MacKillop J, et al. Genome-wide association studies of impulsive personality traits (BIS-11 and UPPS-P) and drug experimentation in up to 22,861 adult research participants identify loci in the CACNA1I and CADM2 genes. J Neurosci. 2019;39:2562–72.
pubmed: 30718321 pmcid: 6435820
Gonzalez-Nunez V. Role of gabra2, GABA(A) receptor alpha-2 subunit, in CNS development. Biochem Biophys Rep. 2015;3:190–201.
pubmed: 29124181 pmcid: 5668850
Wilkinson DG. Multiple roles of eph receptors and ephrins in neural development. Nat Rev Neurosci. 2001;2:155–64.
pubmed: 11256076 doi: 10.1038/35058515
Bahrami S. et al. Genetic loci shared between major depression and intelligence with mixed directions of effect. Nat Hum Behav. 2021;5:1–7.
doi: 10.1038/s41562-020-01031-2
Lejuez CW, Aklin WM, Zvolensky MJ, Pedulla CM. Evaluation of the balloon analogue risk task (BART) as a predictor of adolescent real-world risk-taking behaviours. J Adolesc. 2003;26:475–9.
pubmed: 12887935 doi: 10.1016/S0140-1971(03)00036-8
Pedersen A, Göder R, Tomczyk S, Ohrmann P. Risky decision-making under risk in schizophrenia: a deliberate choice? J Behav Ther Exp Psychiatry. 2017;56:57–64.
pubmed: 27568887 doi: 10.1016/j.jbtep.2016.08.004
Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet. 2018;19:581–90.
pubmed: 29789686 doi: 10.1038/s41576-018-0018-x
Lally J, MacCabe JH. Personalised approaches to pharmacotherapy for schizophrenia. BJPsych Adv. 2016;22:78–86.
doi: 10.1192/apt.bp.114.013433
DeWitt SJ, Aslan S, Filbey FM. Adolescent risk-taking and resting state functional connectivity. Psychiatry Res Neuroimaging. 2014;222:157–64.
doi: 10.1016/j.pscychresns.2014.03.009
Chein JM, Albert D, O’Brien L, Uckert K, Steinberg L. Peers increase adolescent risk taking by enhancing activity in the brain’s reward circuitry. Dev Sci. 2011;14:F1–10.
pubmed: 21499511 pmcid: 3075496 doi: 10.1111/j.1467-7687.2010.01035.x
Chase HW, Fournier JC, Bertocci MA, Greenberg T, Aslam H, Stiffler R, et al. A pathway linking reward circuitry, impulsive sensation-seeking and risky decision-making in young adults: identifying neural markers for new interventions. Transl Psychiatry. 2017;7:e1096–e1096.
pubmed: 28418404 pmcid: 5416701 doi: 10.1038/tp.2017.60
Schneider S, Peters J, Bromberg U, Brassen S, Miedl SF, Banaschewski T, et al. Risk taking and the adolescent reward system: a potential common link to substance abuse. Am J Psychiatry. 2012;169:39–46.
pubmed: 21955931 doi: 10.1176/appi.ajp.2011.11030489
Nestler EJ, Hyman SE, Malenka RC. Molecular neuropharmacology: a foundation for clinical neuroscience. Pennsylvania: McGraw-Hill Medical; 2001.
Phillips ML, Swartz HA. A critical appraisal of neuroimaging studies of bipolar disorder: toward a new conceptualization of underlying neural circuitry and a road map for future research. Am J Psychiatry. 2014;171:829–43.
pubmed: 24626773 pmcid: 4119497 doi: 10.1176/appi.ajp.2014.13081008
Strauss GP, Waltz JA, Gold JM. A review of reward processing and motivational impairment in schizophrenia. Schizophr Bull. 2014;40:S107–16.
pubmed: 24375459 doi: 10.1093/schbul/sbt197

Auteurs

Guy Hindley (G)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway. g.f.l.hindley@medisin.uio.no.
Psychosis Studies, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK. g.f.l.hindley@medisin.uio.no.

Shahram Bahrami (S)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway.

Nils Eiel Steen (NE)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway.

Kevin S O'Connell (KS)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway.

Oleksandr Frei (O)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway.
Center for Bioinformatics, Department of Informatics, University of Oslo, Blindern, 0316, Oslo, Norway.

Alexey Shadrin (A)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway.

Francesco Bettella (F)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway.

Linn Rødevand (L)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway.

Chun C Fan (CC)

Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.
Multimodal Imaging Laboratory, University of California San Diego, La Jolla, CA, 92093, USA.

Anders M Dale (AM)

Department of Neurology, Division of Clinical Neuroscience, Oslo University Hospital, Oslo, Norway.
Department of Radiology, University of California, San Diego, La Jolla, CA, 92093, USA.
Department of Cognitive Science, University of California, San Diego, La Jolla, CA, USA.
Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA.

Srdjan Djurovic (S)

Department of Medical Genetics, Oslo University Hospital, Oslo, Norway.
NORMENT, Department of Clinical Science, University of Bergen, Bergen, Norway.

Olav B Smeland (OB)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway.

Ole A Andreassen (OA)

NORMENT, Institute of Clinical Medicine, University of Oslo and Division of Mental Health and Addiction, Oslo University Hospital, 0407, Oslo, Norway. ole.andreassen@medisin.uio.no.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH